Clinical application of ghrelin for diabetic peripheral neuropathy
| Autor: | Kazuhiro Nagamine, Hideyuki Sakoda, Masamitsu Nakazato, Hiroaki Ueno, Wakaba Tsuchimochi, Kazutaka Shiomi, Tomomi Shiiya, Kenji Kangawa |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Diabetic neuropathy Endocrinology Diabetes and Metabolism Neural Conduction Sural nerve Type 2 diabetes Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Endocrinology Diabetic Neuropathies Sural Nerve Diabetes mellitus Internal medicine Medicine Humans Aged C-Peptide business.industry Human Growth Hormone Therapeutic effect Middle Aged medicine.disease Symptomatic relief Ghrelin 030104 developmental biology Peripheral neuropathy Diabetes Mellitus Type 2 Female business 030217 neurology & neurosurgery |
| Zdroj: | Endocrine journal. 64 |
| ISSN: | 1348-4540 |
| Popis: | Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes, and its progression significantly worsens the patient's quality of life. Although several drugs are available for DPN, all of these provide only symptomatic relief. We investigated the therapeutic effects of ghrelin for DPN, based on its various physiological functions. Seven patients with type 2 diabetes with typical clinical signs and symptoms of DPN were hospitalized. Synthetic human ghrelin (1.0 μg/kg) was administered intravenously for 14 days. Motor nerve conduction velocity (MCV) of the posterior tibial nerve improved significantly after the treatment, compared to that at baseline (35.1 ± 1.8 to 38.6 ± 1.8 m/s, p < 0.0001), while the MCV in six untreated patients did not change throughout hospitalization. The subjective symptoms assessed based on the total symptom score also significantly improved (15.6 ± 3.1 to 11.1 ± 2.2, p = 0.047). Although sensory nerve conduction velocity (SCV) of the sural nerve could not be detected in three patients at baseline, it was detected in two of the three patients after 14 days of ghrelin administration. Overall, SCV did not change significantly. Plasma glucose, but not serum C peptide, levels during a liquid meal tolerance test significantly improved after treatment. These results suggest that ghrelin may be a novel therapeutic option for DPN; however, a double-blind, placebo-controlled trial is needed in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|